p-(2-cyclopropylethoxy)benzoyl chloride | 756478-85-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-(2-cyclopropylethoxy)benzoyl chloride
• 英文别名: 4-(2-Cyclopropylethoxy)benzoyl chloride
• CAS: 756478-85-0
• 化学式: C₁₂H₁₃ClO₂
• 分子量: 224.687
• InChiKey: ZVAFOPALZJFHPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  p-(2-cyclopropylethoxy)benzoyl chloride 在 tris(triphenylphosphine)rhodium(l) chloride 氢气 、 sodium acetate 、 乙酸酐 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 8.0h， 生成 N-{1-(4-Cyclopropylbenzyl)-2-[(2-hydroxyethyl)amino]-2-oxoethyl}-4-(2-cyclopropylethoxy)benzamide
  参考文献：
  名称：

  SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

  摘要：

  公开号：

  EP1908466B1
• 作为产物：
  描述：

  2-环丙基乙醇 在 lithium hydroxide 、 草酰氯 、 水 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 50.58h， 生成 p-(2-cyclopropylethoxy)benzoyl chloride
  参考文献：
  名称：

  SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

  摘要：

  公开号：

  EP1880720B1

文献信息

• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2261213A1

  公开（公告）日：2010-12-15

  The present invention provides to a compound having melanin-concentrating hormone receptor antagonistic action and low toxicity, and useful as a agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有黑色素浓集激素受体拮抗作用和低毒性的化合物，可用作预防或治疗肥胖等疾病的药剂。本发明涉及一种由下式（I）表示的化合物：其中每个符号如规范中定义的，或其盐。
• Synthesis, Structure–Activity Relationship, and Pharmacological Studies of Novel Melanin-Concentrating Hormone Receptor 1 Antagonists 3-Aminomethylquinolines: Reducing Human Ether-a-go-go-Related Gene (hERG) Associated Liabilities
  作者：Shizuo Kasai、Makoto Kamata、Shinichi Masada、Jun Kunitomo、Masahiro Kamaura、Tomohiro Okawa、Kazuaki Takami、Hitomi Ogino、Yoshihide Nakano、Shuntarou Ashina、Kaoru Watanabe、Tomoko Kaisho、Yumi N. Imai、Sunghi Ryu、Masaharu Nakayama、Yasutaka Nagisa、Shiro Takekawa、Koki Kato、Toshiki Murata、Nobuhiro Suzuki、Yuji Ishihara

  DOI：10.1021/jm300167z

  日期：2012.5.10

  Recently, we discovered 3-aminomethylquinoline derivative 1, a selective, highly potent, centrally acting, and orally bioavailable human MCH receptor 1 (hMCHR1) antagonist, that inhibited food intake in F344 rats with diet-induced obesity (DIO). Subsequent investigation of 1 was discontinued because 1 showed potent hERG K+ channel inhibition in a patch-clamp study. To decrease hERG K+ channel inhibition, experiments with ligand-based drug designs based on 1 and a docking study were conducted. Replacement of the terminal p-fluorophenyl group with a cyclopropylmethoxy group, methyl group introduction on the benzylic carbon at the 3-position of the quinoline core, and employment of a [2-(acetylamino)ethyl]amino group as the amine portion eliminated hERG K+ channel inhibitory activity in a patch-clamp study, leading to the discovery of N-3-[(1R)-1-[2-(acetylamino)ethyl]amino}ethyl]-8-methylquinolin-7-yl}-4-(cyclopropylmethoxy)benzamide (R)-10h. The compound (R)-10h showed potent inhibitory activity against hMCHR1 and dose-dependently suppressed food intake in a 2-day study on DIO-F344 rats. Furthermore, practical chiral synthesis of (R)-10h was performed to determine the molecule's absolute configuration.
• Development of prostaglandin D2 receptor antagonist: discovery of highly potent antagonists
  作者：Kazuhiko Torisu、Kaoru Kobayashi、Maki Iwahashi、Yoshihiko Nakai、Takahiro Onoda、Toshihiko Nagase、Isamu Sugimoto、Yutaka Okada、Ryoji Matsumoto、Fumio Nanbu、Shuichi Ohuchida、Hisao Nakai、Masaaki Toda

  DOI：10.1016/j.bmc.2004.06.024

  日期：2004.9

  The process of discovery for highly potent prostaglandin D-2 (PGD(2)) receptor antagonists is reported. A series of N-(p-alkoxy)benzoyl-2-methylindole-4-acetic acids were synthesized and identified as a new class of selective PGD(2) receptor antagonists. Most of them exhibited strong PGD(2) receptor antagonism in binding studies and the cAMP formation assay. The structure-activity relationships (SAR), including subtype selectivity of the synthesized compounds, are also discussed. (C) 2004 Elsevier Ltd. All rights reserved.